Humacyte, Inc.

Humacyte, Inc., a regenerative medicine company developing bioengineered human acellular vessels, completed its business combination with Alpha Healthcare Acquisition Corp. III (Nasdaq: AHAC) in August 2021, sponsored by Alpha Healthcare Investors III LLC. The blank-check vehicle conducted its initial public offering in 2021 and brought Humacyte into the public markets under the ticker HUMA following the de-SPAC transaction. The company filed an 8-K with the Securities and Exchange Commission on June 13, 2022, a post-merger current report disclosure. Humacyte operates in the biotechnology and regenerative medicine sector, with its pipeline centered on off-the-shelf tissue-engineered vascular grafts for surgical use. Sign up at SpacDesk for full filing history, deal analytics, and real-time SPAC data on Humacyte and hundreds of other transactions.